Member Info for dactions

In the regular review of the Woodford Funds - in this case that of March published yesterday, there was the following comment raised by an investor and answered by their senior analyst as follows: Quote: I wondered if you could comment on the massive sell off of Astra Zenica, is this to do with the disbursements required as the main fund has dropped so much ( nearly 3b !!!). Also, anything to say about Reneuron? Since the reverse split the sp has been slipping quite dramatically, is this just short attack or is something else going on with company? Many thanks. Mike. Hi Mike, You can find an explanation of the recent reduction in the AstraZeneca position here: https://woodfordfunds.com/funds/holdings/astrazeneca/ As we have said in the latest commentary, �Not a great deal has changed as far as the investment case for AstraZeneca is concerned. But a lot of other stocks have become increasingly attractive from a valuation perspective.� It�s not always possible to respond on every company we�re invested in for a variety of reasons. We have nothing specific to say on ReNeuron right now, other than we continue to believe that its technology platform is very valuable � significantly more so than the current market price would imply. Kind regards Mitchell Fraser-Jones

Re the surprising fall today, possibly a large delayed sell going through ? Remember there will be some that are nursing large losses given the cash raising at 6.5p previously.

CRe the surprising fall today, possibly a large delayed sell going through ?

The interview is short & sweet but enticingly positive !?

Thank you Primal - it was really good to see SOH's comments. Thanks for taking the trouble to both get the info and share it.

"For the conspiracy theorists why has Reneuron posted this innocuous RNS before year end? It�s a rhetorical question!" It's a good rhetorical question Sheer and I agree with you jackdaw - there's not really a lot there (in the RNS). That kind of statement we had this morning would have been more useful in past months/years if it had been done on a regular basis before the prolonged sp deline set in. We blamed their PR - their lack of judgement in keeping the market regularly informed. It may not have worked but I truly doubt we would have reached the level we're now at ! However, we'll never know.

This afternoon's sells spoiled what could have been a stronger blue day. I can only assume that as we're coming to the end of the tax year, TPG will have lost money for most investors this past 12 months - whatever we might think about good prospects going forward.

I quite agree Sisyphus - I added a few this morning but unfortunately my assets are tied up elsewhere. The outlook does look good and it's coming together at last.

Following on from other recently reported contract wins, today's announcement details a contract in a different direction than before. Assuming the initial stage goes well, the extended contract is valued at a decent �2millions, The outlook is really looking good I think. QUOTE: Information Assurance contract win TP Group (AIM: TPG), the specialist services and engineering group, is pleased to announce that it has been signed a three year agreement to deliver information assurance services to a UK Government agency. The work will commence immediately with a value of c. �0.7 million in year one, and with options for two further years that could take the total contract value to c. �2 million. Phil Cartmell, Chief Executive Officer of TP Group commented: "This contract award is another step forward in the evolution of our Services business and demonstrates our growing reputation to support critical programmes within Governments." ENDQUOTE

As a LTH, I don't know what to make of today's RNS. Is this what was anticipated in people's comments last week ? It seems to be an announcement, that reiterates the company's objectives, rather than new news. I wonder if others feel likelwise ?

Malcolm Graham-Wood has just released this blog update on SRON: Saffron/Coro- James Menzies joins the Holy Trinity� Saffron has announced today that James Menzies is to join as CEO with effect from the first of May. James was founder of Salamander Energy, later taken over by Ophir Energy in a transaction worth $850m in 2015. Menzies will join the board with Sara Edmonson as Deputy Chief Executive and will lead the process of building the business in SE Asia where I am sure a number of opportunities are well advanced. This appointment is a real game changer for Coro and will surely mean that the company is set for dynamic growth in the region and the aim of building a business of �material size� becomes a genuine reality. James Menzies can provide the team with deep regional knowledge and combined with the local experience from Chairman James Parsons will provide a launch pad for the company that even the most optimistic shareholder might not have dreamed of.

Agree Sisyphus. Here's me earlier today talking of no news - and the website write-up on Jon Constable's progress within TPG is a very heartening read - thanks for highlighting it,

My loss is massive too - but I can't afford to write them off Costello. These have the means to come good and I echo Freddie's points re. their marketing strategy (or not as seems to be the case !).

Although the Buys were small sized they were relatively numerous and Falanx is a thin market - reasons to be cheerful - as the song goes.

Here's the link if you want to see for yourself. http://www.edisoninvestmentresearch.com/research/report/reneuron-group534676/full

A bit of comfort whilst us LTHs sweat even more with the miserable shareprice, Edison published these comments on RENE: Quote: ReNeuron�s recent 100 for 1 share consolidation was a benign and cosmetic �tidy up� of its historical capital structure. The share price of ReNeuron is trading at 52-week lows and the recent consolidation may have been an unrelated or an unintended cause for concern for some investors. ReNeuron�s valuation is now below its c �40m cash position. In this update, we offer some possible thoughts on this overreaction and, in the absence of operational newsflow, our forecasts and valuation are largely unchanged. Share consolidation just cosmetic: ReNeuron completed a 1 for 100 share consolidation, which was supported and requested by some institutional holders in order to improve marketability, just before a period of intense stock market volatility. It is not possible to know investors� reasons for selling but some may have mistakenly taken the share price rise as an opportunity to �take profits�. ReNeuron�s stock price is now not just trading at 52-week lows, but also below its cash balance. Our valuation of ReNeuron has hardly changed as a result of the share consolidation. A flight away from risky assets? A share consolidation is in and of itself not an obvious signal to sell the stock, since the company�s market capitalisation does not change. In the period of market volatility from late January, investors may have sold risky and even risk-free assets in a flight away from risk. To the inexperienced investor, a share consolidation gives the illusion of a higher share price that might have resulted in an investment decision. Investors may also have been worried that the first patient dosed in the late-stage US clinical trial in chronic stroke has not yet been announced. We expect the announcement that the first US chronic stroke patient has been dosed in H118. Loss-making companies can be valued below cash if some of that cash has to be spent to generate a technology value. In ReNeuron�s case any technology value it has generated to date is being discounted. ReNeuron�s lead product is about to start the first of two studies required for FDA approval, and positive long-term Phase II data was recently announced at the American Heart Association meeting. Valuation: Slightly higher after the consolidation We have updated our model for the share consolidation (which did not change our operating assumptions) and for our estimates of the FY17 year-end cash position, and have rolled our DCF forward by one quarter. Despite the share consolidation and market volatility, our valuation of �290m (previously �286m) remains largely unchanged. End quote Hope those comments help a bit. Good luck.

I agree Boyzee - there has been a considerable number of RNS but patience startes to wear a bit thin as it's the figures that will move the SP now. Still, I suppose today's RNS offering the hint of future dividends is a tad more positive in the direction we're all waiting for ?

I agree DAR - whilst I'm sure the company is ticking along OK, I had more expecations of some worthy news before now.

Their monthly report shows the following for Rene: QUOTE: ReNeuron is focused on two cell therapy-based programmes. This includes the CTX neural stem cell programme which recently announced that positive response rates in key measures were sustained after 12 months of treatment. They also recently announced they will be moving forward with a Phase IIb in the US with data expected around H219. It also includes the hRPC (human retinal progenitor cells) programme for retinitis pigmentosa (currently in Phase II). It will also be commencing a Phase II trial in cone-rod dystrophy. ReNeuron has promising early data for its exosome nanomedicine platform in oncology. INDUSTRY OUTLOOK Limited drug development has targeted chronic stroke to date, which is the area in which ReNeuron is attempting to demonstrate a meaningful reduction in disability. If shown, it would offer a compelling case for further development and/or partnering. End quote

oops - read - Pfizer/Viagra link.